Abstract:Antibodies are essential research tools whose performance directly impacts research conclusions and reproducibility. Owing to its central role in Alzheimer's disease and other dementias, hundreds of distinct antibody clones have been developed against the microtubule-associated protein Tau and its multiple proteoforms. Despite this breadth of offer, limited understanding of their performance and poor antibody selectivity have hindered research progress. Here, we validate a large panel of Tau antibodies by Western blot (79 reagents) and immunohistochemistry (35 reagents). We address the reagents' ability to detect the target proteoform, selectivity, the impact of protein phosphorylation on antibody binding and performance in human brain samples. While most antibodies detected Tau at high levels, many failed to detect it at lower, endogenous levels. By WB, non-selective binding to other proteins affected over half of the antibodies tested, with several cross-reacting with the related MAP2 protein, whereas the "oligomeric Tau" T22 antibody reacted with monomeric Tau by WB, thus calling into question its specificity to Tau oligomers. Despite the presumption that "total" Tau antibodies are agnostic to post-translational modifications, we found that phosphorylation partially inhibits binding for many such antibodies, including the popular Tau-5 clone. We further combine high-sensitivity reagents, mass-spectrometry proteomics and cDNA sequencing to demonstrate that presumptive Tau "knockout" human cells continue to express residual protein arising through exon skipping, providing evidence of previously unappreciated gene plasticity. Finally, probing of human brain samples with a large panel of antibodies revealed the presence of C-term-truncated versions of all main Tau brain isoforms in both control and tauopathy donors. Ultimately, we identify a validated panel of Tau antibodies that can be employed in Western blotting and/or immunohistochemistry to reliably detect even low levels of Tau expression with high selectivity. This work represents an extensive resource that will enable the re-interpretation of published data, improve reproducibility in Tau research, and overall accelerate scientific progress.

In need of a specific antibody against the oxytocin receptor for neuropsychiatric research: A KO validation study

Validation of a newly generated oxytocin antibody for enzyme-linked immunosorbent assays

Specificity of plasma oxytocin immunoassays: A comparison of commercial assays and sample preparation techniques using oxytocin knockout and wildtype mice

Neurophysin I is an Analytically Robust Surrogate Biomarker for Oxytocin

Advances in human oxytocin measurement: challenges and proposed solutions

Binding Affinity, Selectivity, and Pharmacokinetics of the Oxytocin Receptor Antagonist L-368,899 in the Coyote ( Canis latrans )

Development of a 5-HT7 receptor antibody for the rat: the good, the bad, and the ugly

Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice

- Inaccuracies in oxytocin assays: the Trojan horse of solid-phase extraction procedures?

Assessment of A Method to Characterize Antibody Selectivity and Specificity for Use in Immunoprecipitation

Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications

Molecular Basis of Oxytocin Receptor Signalling in the Brain: What We Know and What We Need to Know

Specificity Controls for Immunocytochemistry

Near infrared fluorescent nanosensors for high spatiotemporal oxytocin imaging

SHANK3 Antibody Validation: Differential Performance in Western Blotting, Immunocyto- and Immunohistochemistry

Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry

Highly drug/target-tolerant neutralizing antibody (NAb) assay development through target-based drug depletion and drug-based NAb extraction for an anti-EGFR therapeutic monoclonal antibody

Overview of Human Oxytocin Research

Structurally related peptide impurity identification and accurate quantification for synthetic oxytocin by liquid chromatography-high-resolution mass spectrometry

Oxytocin effects on brain and behavior are influenced by dose-frequency and receptor genotype: therapeutic implications

Genotype and dose-frequency determine acute and chronic effects of oxytocin on amygdala fear responses in humans: therapeutic implications